World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
46783
World Ranking
8167
National Ranking
468

Overview

Volker Heinemann is affiliated with Ludwig-Maximilians-Universität München in Germany. Their research focuses primarily on medicine with a substantial emphasis on oncology and related subfields.

The key areas of their work include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Pathology and Forensic Medicine
  • Surgery

The main topics investigated in their publications cover:

  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Pancreatic and Hepatic Oncology Research
  • Gastric Cancer Management and Outcomes
  • Genetic factors in colorectal cancer
  • Lung Cancer Treatments and Mutations
  • Hepatocellular Carcinoma Treatment and Prognosis

Heinemann has contributed to a range of recent papers, including:

  • "Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial" (2023), published in The Lancet
  • "Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma" (2020), published in Journal of Clinical Oncology
  • "FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial" (2020), published in British Journal of Cancer
  • "Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial" (2020), published in The Lancet. Gastroenterology & Hepatology
  • "Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial" (2022), published in Journal of Clinical Oncology

The frequent coauthors collaborating with Heinemann include:

  • Sebastian Stintzing
  • Dominik Paul Modest
  • Arndt Stahler
  • Swantje Held
  • Ludwig Fischer von Weikersthal

The scientist has published extensively in several key venues, such as:

  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Annals of Oncology
  • Journal of Cancer Research and Clinical Oncology
  • ESMO Open

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

    Salah-Eddin Al-Batran;Nils Homann;Claudia Pauligk;Thorsten O Goetze

  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

    Volker Heinemann;Ludwig Fischer von Weikersthal;Thomas Decker;Alexander Kiani

  • The Liver Tumor Segmentation Benchmark (LiTS)

    Patrick Bilic;Patrick Ferdinand Christ;Eugene Vorontsov;Grzegorz Chlebus

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

    Eric Van Cutsem;Heinz Josef Lenz;Claus Henning Köhne;Volker Heinemann

  • Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

    Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann

  • Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

    Sabine Tejpar;Sebastian Stintzing;Fortunato Ciardiello;Josep Tabernero

  • nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

    David Goldstein;Robert Hassan El-Maraghi;Pascal Hammel;Volker Heinemann

  • Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    Jan Franko;Qian Shi;Jeffrey P Meyers;Timothy S Maughan

  • Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

    Volker Heinemann;Stefan Boeck;Axel Hinke;Roberto Labianca

  • The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

    Julian Walter Holch;Ingrid Ricard;Sebastian Stintzing;Dominik Paul Modest

  • Advances in cancer immunotherapy 2019 – latest trends

    Stephan Kruger;Stephan Kruger;Matthias Ilmer;Matthias Ilmer;Sebastian Kobold;Bruno L. Cadilha

  • Addressing the challenges of pancreatic cancer: future directions for improving outcomes

    Manuel Hidalgo;Stefano Cascinu;Jörg Kleeff;Roberto Labianca

  • Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.

    Hans-Joachim Stemmler;Manfred Schmitt;Amina Willems;Helga Bernhard

  • Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report

    M.J. Duffy;C. Sturgeon;R. Lamerz;C. Haglund

  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

    Sebastian Stintzing;Sebastian Stintzing;Dominik P Modest;Dominik P Modest;Lisa Rossius;Markus M Lerch

  • Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

    David Malka;Pascale Cervera;Stéphanie Foulon;Tanja Trarbach

  • [Update S3-guideline "colorectal cancer" 2008].

    W. Schmiegel;A. Reinacher-Schick;D. Arnold;U. Graeven

  • SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

    Guy A. van Hazel;Volker Heinemann;Navesh K. Sharma;Michael P.N. Findlay

Frequent Co-Authors

Andreas Jung
Andreas Jung University of Zurich
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Alfredo Falcone
Alfredo Falcone University of Pisa
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Werner Scheithauer
Werner Scheithauer Medical University of Vienna
Jens Werner
Jens Werner Ludwig-Maximilians-Universität München
Thomas Decker
Thomas Decker University of Vienna
Marc Peeters
Marc Peeters University of Antwerp
Jens T. Siveke
Jens T. Siveke German Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing Medicine in the USA is highly competitive, there are many related online degree options for those interested in healthcare careers. For aspiring leaders, online health administration programs offer flexible pathways to managerial roles in hospitals and clinics. These programs are ideal for students seeking to impact healthcare systems without a traditional medical degree.

Many nurses build advanced practice careers by enrolling in adn to np programs online, which allow registered nurses with associate degrees to become nurse practitioners through accelerated distance learning options. These bridge programs expand career opportunities in specialized patient care fields.

Another essential area is nutrition. Those interested in wellness and disease prevention can consider a nutritionist online degree, which opens doors to careers in clinical settings, community programs, or private counseling.

When choosing any healthcare administration path, understanding how to evaluate healthcare administration degree programs is critical. Accreditation, curriculum quality, and career outcomes should all factor into your decision to ensure your investment leads to advancement in the healthcare industry.

Best Scientists Citing Volker Heinemann

Trending Scientists

Recently Published Articles